H.C. Wainwright Initiates Coverage on SINTX Technologies with Buy Rating, Highlighting Silicon Nitride Platform Opportunity

April 23, 2026

Independent analyst coverage underscores SINTX’s transition to a commercial-stage biomaterials company, citing its silicon nitride technology, recent FDA clearance and first human implant, and a scalable platform strategy across orthopedics and adjacent healthcare markets.

Read More »